Title:
COMBINATION ANTI-EPN1 AND ANTI-PD-L1 ANTIBODY THERAPIES
Document Type and Number:
WIPO Patent Application WO/2023/225613
Kind Code:
A3
Abstract:
This invention relates to treating cancer by targeting the cell membrane-localized adaptor protein, Epsin-1 (EPN1), in combination with targeting one or more immune checkpoint proteins, including targeting programmed cell death-ligand 1 (PD-L1) and/or targeting Programmed cell death protein 1 (PD-1)
Inventors:
ROBINSON MATTHEW (US)
MORIN MICHAEL JOHN (US)
DOWLING JOHN P (US)
SHEN FANG (US)
MORIN MICHAEL JOHN (US)
DOWLING JOHN P (US)
SHEN FANG (US)
Application Number:
PCT/US2023/067195
Publication Date:
December 28, 2023
Filing Date:
May 18, 2023
Export Citation:
Assignee:
IMMUNOME INC (US)
International Classes:
C07K16/28; A61K39/395; A61P35/00
Foreign References:
| US20210347895A1 | 2021-11-11 | |||
| US20120046181A1 | 2012-02-23 |
Attorney, Agent or Firm:
BELLUM, Stephen C. (US)
Download PDF: